A new Novo Nordisk drug called liraglutide, which it's marketing as Victoza, may provide an answer to both problems.
A study conducted in Denmark found today that it's safe and effective as a treatment for Type II diabetes. (Yes, it beat the placebo, too.)
Novo Nordisk is based in Denmark, and while its stock rose in response to the news it fell back to pre-announcement levels within a day.
The drug is given once a day by injection. While many Type I diabetics are accustomed to injecting themselves with insulin, many Type II diabetics are given pills as a first-line treatment.
Arne Astrup, who conducted the study, told the BBC the drug mimics the behavior of a natural hormone called GLP-1, which is released by the small intestine after you eat. The hormone tells the brain you're full and the body to produce digestive insulin, but the effect dissipates quickly.
The drug allows your body to feel the effects of GLP-1 for a full 24 hours, making it resistant to the body's natural self-destruct mechanism.
Critics will note that this is an injected drug, while Xenical is a tablet. Some are also questioning its use in weight loss.